Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-26T11:05:09.784Z Has data issue: false hasContentIssue false
  • English
  • Français

Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections – CORRIGENDUM

Published online by Cambridge University Press:  08 October 2013

Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Corrigendum
Information
Parasitology , Volume 141 , Issue 1: Symposia of the British Society for Parasitology volume 49 Emerging paradigms in anti-infective drug design , January 2014 , pp. 147
Copyright
Copyright © Cambridge University Press 2013 

In the recently published paper by Don and Ioset, the authors would like to amend 2 incorrect figures found on the fifth page in the last complete paragraph.

AstraZeneca (2·5 million) and Bayer Pharma AG (1·4 million)

Should read

AstraZeneca (1·4 million) and Bayer Pharma AG (2·5 million)

References

Don, R., Ioset, J.-R.Screening strategies to identify new chemical diversity for drug development. Parasitology, Published online 28 August 2013, doi: 10.1017/S003118201300142.Google ScholarPubMed